2019
Tobacco‐21 laws and young adult smoking: quasi‐experimental evidence
Friedman AS, Buckell J, Sindelar JL. Tobacco‐21 laws and young adult smoking: quasi‐experimental evidence. Addiction 2019, 114: 1816-1823. PMID: 31342591, PMCID: PMC7233410, DOI: 10.1111/add.14653.Peer-Reviewed Original ResearchThe impact of flavors, health risks, secondhand smoke and prices on young adults’ cigarette and e‐cigarette choices: a discrete choice experiment
Buckell J, Sindelar JL. The impact of flavors, health risks, secondhand smoke and prices on young adults’ cigarette and e‐cigarette choices: a discrete choice experiment. Addiction 2019, 114: 1427-1435. PMID: 30866132, PMCID: PMC6639008, DOI: 10.1111/add.14610.Peer-Reviewed Original ResearchConceptsE-cigarettesHealth harmsYoung adultsSmoking groupNational Health Interview SurveySecondhand smoke risksHealth Interview SurveyShort-term health risksHealth risksSecondhand smokeSmoking typesYoung adults' preferencesDiscrete choice experimentCigarettesInterview SurveySmoke risksAdultsOnline discrete choice experimentCensus regionRiskCigarette pricesImpact of flavourCandy flavorsGroupHealthPatterns of Youth Cigarette Experimentation and Onset of Habitual Smoking
Friedman AS, Buckell J, Sindelar JL. Patterns of Youth Cigarette Experimentation and Onset of Habitual Smoking. American Journal Of Preventive Medicine 2019, 56: 803-810. PMID: 31005466, PMCID: PMC6594175, DOI: 10.1016/j.amepre.2019.02.009.Peer-Reviewed Original Research
2008
Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients
Jones ES, Moore BA, Sindelar JL, O’Connor P, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug And Alcohol Dependence 2008, 99: 132-140. PMID: 18804923, PMCID: PMC2646001, DOI: 10.1016/j.drugalcdep.2008.07.013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBuprenorphineCohort StudiesCost of IllnessCosts and Cost AnalysisData Interpretation, StatisticalFemaleHealth PersonnelHumansMaleMethadoneMiddle AgedNarcoticsOpioid-Related DisordersPhysicians' OfficesSocioeconomic FactorsSubstance Abuse DetectionSubstance Abuse Treatment CentersTreatment OutcomeYoung AdultConceptsOffice-based treatmentOpioid dependencePatient costsClinical contactMonthly medication costsOffice-based buprenorphineOffice-based methadoneMonths of treatmentAnalysis of treatmentTotal monthly costsChi-square testMonths of maintenanceStable patientsMedication costsPatientsMethadoneMonthly costBuprenorphineTreatmentMonthsStatistical comparisonCost estimatesClinic
2007
The cost‐effectiveness of four treatments for marijuana dependence
Olmstead TA, Sindelar JL, Easton CJ, Carroll KM. The cost‐effectiveness of four treatments for marijuana dependence. Addiction 2007, 102: 1443-1453. PMID: 17645430, PMCID: PMC2398724, DOI: 10.1111/j.1360-0443.2007.01909.x.Peer-Reviewed Original ResearchConceptsMET/CBTDrug counselingContingency managementPatient outcomesYoung adultsEffective treatmentMarijuana dependenceAcceptability curvesIncremental cost-effectiveness ratioRandomized clinical trialsCost of therapyPatient outcome measuresCost-effective dependsCost-effectiveness ratioSubstance abuse clinicsCost-effective treatmentCM procedureClinical trialsOutcome measuresUrine specimenUrine specimensAdditional weeksAdditional studiesMarijuana abstinenceLonger durationSmoking Status as a Clinical Indicator for Alcohol Misuse in US Adults
McKee SA, Falba T, O’Malley S, Sindelar J, O’Connor P. Smoking Status as a Clinical Indicator for Alcohol Misuse in US Adults. JAMA Internal Medicine 2007, 167: 716-721. PMID: 17420431, PMCID: PMC2869385, DOI: 10.1001/archinte.167.7.716.Peer-Reviewed Original ResearchConceptsClinical care guidelinesSmoking statusPositive predictive valueClinical indicatorsAlcohol misuseUS adultsPositive likelihood ratioCurrent smokingCare guidelinesOdds ratioAlcohol diagnosisAssociated Disabilities Interview Schedule-IVPredictive valueHazardous drinkingPrimary care settingAlcohol-related diagnosesConfidence intervalsAlcohol use disorderNational Epidemiological SurveyAlcohol use diagnosisHazardous drinking behaviorLikelihood ratioOccasional smokersPrimary careDaily smokersWhat do we get for our money? Cost‐effectiveness of adding contingency management
Sindelar J, Elbel B, Petry NM. What do we get for our money? Cost‐effectiveness of adding contingency management. Addiction 2007, 102: 309-316. PMID: 17222286, DOI: 10.1111/j.1360-0443.2006.01689.x.Peer-Reviewed Original Research
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeEffectiveness of Switching Antipsychotic Medications
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of Switching Antipsychotic Medications. American Journal Of Psychiatry 2006, 163: 2090-2095. PMID: 17151159, DOI: 10.1176/ajp.2006.163.12.2090.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsBenzodiazepinesCross-Over StudiesDibenzothiazepinesDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleHumansMiddle AgedOlanzapinePatient DropoutsPsychotherapyQuetiapine FumarateResearch DesignRisperidoneSchizophreniaSchizophrenic PsychologySelection BiasSurvival AnalysisTreatment OutcomeConceptsMedication changesDifferent antipsychoticsCause treatment discontinuationCurrent medication regimensClinical Antipsychotic TrialsPhase 1 analysisPhase 1 findingsBaseline medicationsSwitching medicationsTreatment discontinuationMedication regimensPrimary outcomeMedication effectivenessAntipsychotic medicationAntipsychotic TrialsMedicationsAntipsychoticsClinical situationsOlanzapinePatientsRisperidoneIntervention effectivenessDearth of informationDiscontinuationRandom assignment
2005
If smoking increases absences, does quitting reduce them?
Sindelar JL, Duchovny N, Falba TA, Busch SH. If smoking increases absences, does quitting reduce them? Tobacco Control 2005, 14: 99. PMID: 15791019, PMCID: PMC1747999, DOI: 10.1136/tc.2003.005884.Peer-Reviewed Original Research
2004
To what extent are key services offered in treatment programs for special populations?
Olmstead T, Sindelar JL. To what extent are key services offered in treatment programs for special populations? Journal Of Substance Use And Addiction Treatment 2004, 27: 9-15. PMID: 15223088, DOI: 10.1016/j.jsat.2004.03.004.Peer-Reviewed Original Research